Filing Analysis
TELA Bio, Inc. has amended its previous 8-K to disclose the specific terms of a Separation Agreement with former CEO Antony Koblish following his departure on August 3, 2026.
🚩 Red Flags
- Departure of the Chief Executive Officer (CEO) can create leadership instability in micro-cap companies.
- Significant cash outflow required for severance and COBRA premiums.
📋 Key Facts
- Antony Koblish ceased serving as CEO effective August 3, 2026.
- Separation Agreement entered into on August 7, 2026.
- Severance includes 12 months of base salary paid ratably over a 12-month period.
- The Company will pay COBRA premiums for Mr. Koblish for 12 months if he elects coverage by September 1, 2026.
- All equity awards under the 2019 Equity Incentive Plan are to immediately accelerate and become fully vested as of August 7, 2026.
- Option excise period extended until December 31, 2027, or expiration date.
TELA Bio, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notification that a press release containing these results was issued on August 10, 2026.
📋 Key Facts
- Reported date of event: August 10, 2026
- Reporting period: Second quarter ended June 30, 2026
- The filing includes Exhibit 99.1, which is the official press release containing financial results.
- The information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
TELA Bio, Inc. announced the departure of CEO Antony Koblish and his resignation from the Board, effective August 3, 2026. The company has appointed Heather Getz as the new CEO and a Class II director.
🚩 Red Flags
- Sudden departure of CEO and Board member (though stated as not due to disagreement).
- Significant potential dilution via 'Top-Up Grants' designed to ensure the new CEO holds 5% of the company in the event of a financing.
📋 Key Facts
- Antony Koblish terminated as CEO and principal executive officer on August 3, 2026; termination is treated as 'without cause'.
- Heather Getz appointed as CEO and Class II director, effective August 3, 2026.
- Getz's compensation includes a $650,000 base salary and a 100% target cash bonus.
- Initial equity grants to Getz include 1,365,000 standard options, 1,005,000 premium-priced options, and 500,000 RSUs.
- Includes 'Top-Up Grants' provision: if the company conducts financing within 18 months, Getz receives additional equity to maintain a total grant size equal to 5% of outstanding shares.
TELA Bio reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Key outcomes include the election of Class I directors, ratification of KPMG LLP as auditors, and the approval of an amendment to the 2019 Equity Incentive Plan.
📋 Key Facts
- Stockholders approved an amendment to the Amended and Restated 2019 Equity Incentive Plan to increase authorized shares by 3,500,000 shares.
- Joseph Capper, Betty Jo Rocchio, and William Plovanic were elected as Class I directors until the 2029 Annual Meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Executive compensation was approved on a non-binding advisory basis (Say-on-Pay).
- Total outstanding shares as of the April 24, 2026 record date were 44,765,928.
TELA Bio, Inc. announced its financial results for the first quarter ended March 31, 2026, and updated its corporate investor presentation. The filing serves as a routine quarterly update for investors and does not contain any immediate material structural changes.
📋 Key Facts
- The company reported financial results for the first quarter ended March 31, 2026, on May 12, 2026.
- A press release detailing the financial results was furnished as Exhibit 99.1.
- The company updated its corporate slide deck for use in investor meetings, furnished as Exhibit 99.2.
- The filing was made under Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).
TELA Bio announced a sweeping overhaul of its Board of Directors, with four directors including the Chairman departing, and the appointment/nomination of four high-profile MedTech industry veterans. The company also reported preliminary Q1 2026 revenue of approximately $19.0 million.
🚩 Red Flags
- Mass resignation/departure of four board members simultaneously, representing a significant portion of the board's composition.
- The incoming Chairman, Joseph Capper, is not expected to qualify as an independent director under Nasdaq rules.
📋 Key Facts
- Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, and Federica O'Brien are departing the Board effective after the 2026 Annual Meeting.
- Joseph Capper (CEO of MiMedx and former CEO of BioTelemetry) has been nominated as the new Chairman of the Board.
- Three new independent directors were appointed: Guido Neels (EW Healthcare Partners), Guy Nohra (Alta Partners), and Paul Thomas (CEO of Prominex).
- Preliminary unaudited revenue for the quarter ended March 31, 2026, is estimated at $19.0 million.
- Departing directors were granted an extension of their post-termination option exercise period to 12 months.
TELA Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and updated its corporate investor presentation materials.
📋 Key Facts
- The report was filed on March 24, 2026, covering the fiscal year ended December 31, 2025.
- Item 2.02: Results of Operations and Financial Condition for Q4 and FY 2025 were announced via press release.
- Item 7.01: An updated corporate slide deck (Exhibit 99.2) was released for use in investor meetings.
- The company is listed on the Nasdaq Global Market under the ticker TELA.
TELA Bio, Inc. received a deficiency notice from Nasdaq on March 17, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 days, or until September 14, 2026, to regain compliance with the listing requirements.
🚩 Red Flags
- The stock has traded below $1.00 for 30 consecutive business days, indicating significant market devaluation.
- Potential for a reverse stock split if the share price does not recover organically.
- Risk of delisting from the Nasdaq Global Market if compliance is not achieved by the deadline.
📋 Key Facts
- Notice received from Nasdaq Listing Qualifications Department on March 17, 2026.
- Non-compliance with Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid price.
- The company has an initial 180-day period (until September 14, 2026) to regain compliance.
- To regain compliance, the stock must close at $1.00 or higher for at least 10 consecutive business days.
- A second 180-day extension may be available if the company transfers to the Nasdaq Capital Market.
TELA Bio entered into a $70 million senior secured term loan facility with Perceptive Credit Holdings and simultaneously launched a registered direct offering of common stock and pre-funded warrants. The company is also terminating its existing credit agreement with MidCap Financial Trust to facilitate this new financing.
🚩 Red Flags
- Significant dilution via issuance of warrants to the lender (Perceptive).
- High interest rate structure with a 3.00% penalty margin upon Event of Default.
- Restrictive covenants including minimum liquidity requirement of $5.0 million and revenue maintenance requirements.
- Heavy use of debt/equity financing to fund general corporate purposes, suggesting potential cash runway constraints.
- Pre-funded warrants allow for significant future dilution.
📋 Key Facts
- Entered into a $70M senior secured term loan facility with Perceptive Credit Holdings V, LP (Signing Date: Nov 13, 2025).
- Initial loan amount of $60.0 million to be funded on Nov 14, 2025.
- Includes a $10.0 million delayed draw loan component.
- Maturity date set for November 14, 2030.
- Interest rate: Applicable Margin of 7.85% + Reference Rate or 4.25% (whichever is greater).
- Launched a registered direct offering of 4,189,000 shares at $1.11 per share and up to 7,523,000 pre-funded warrants.
- Expected net proceeds from the offering: approximately $11.9 million.
- Issuance of warrants to Perceptive for up to 2,000,000 shares (Initial) and 333,333 shares (DDL) at an exercise price of $1.11.
- Termination of existing Credit and Security Agreement with MidCap Financial Trust.
TELA Bio, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025 and provided an updated corporate presentation.
📋 Key Facts
- Company announced Q3 2025 financial results on November 13, 2025.
- The company furnished a press release (Exhibit 99.1) containing the earnings data.
- The company updated its corporate slide deck (Exhibit 99.2) for investor meetings.
TELA Bio, Inc. announced the appointment of William Plovanic to its Board of Directors as an independent director on October 31, 2025. The board expanded from six to seven members with this addition.
📋 Key Facts
- Appointment date: October 31, 2025
- New Director: William Plovanic (Class I director)
- Board size increased from 6 to 7 members
- Plovanic's background includes Managing Director at Canaccord Genuity and former CEO/CFO of Obalon Therapeutics
- Initial Equity Award: 17,550 stock options (36-month vesting) and 11,925 RSUs (3-year vesting)
- Annual retainer: $45,000
- Director is deemed independent under Nasdaq rules
TELA Bio, Inc. announced the resignation of Board member Lisa Colleran and her subsequent appointment of Dr. Betty Jo Rocchio to the Board of Directors.
🚩 Red Flags
- None identified; the departure was characterized as non-dispute related.
📋 Key Facts
- Lisa Colleran resigned from the Board, Nominating and Corporate Governance Committee, and Audit Committee effective October 4, 2025.
- The company stated Ms. Colleran's resignation was not due to any disagreement regarding operations, policies, or practices.
- Dr. Betty Jo Rocchio appointed as a Class I director effective October 9, 2025.
- Dr. Rocchio is an independent director with significant healthcare leadership experience (Executive VP at Advocate Health).
- Initial equity award for Dr. Rocchio includes 17,550 stock options and 11,925 RSUs.
- Annual base retainer for Dr. Rocchio is set at $45,000.
TELA Bio, Inc. filed an 8-K to announce its second quarter 2025 financial results and provide an updated corporate presentation for investor meetings.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Second quarter ended June 30, 2025
- The filing includes a press release regarding financial results (Exhibit 99.1)
- The filing includes an updated corporate slide deck for investor relations (Exhibit 99.2)
TELA Bio, Inc. announced a leadership restructuring where Jeffrey Blizard will join as President effective June 2, 2025, while Antony Koblish remains CEO but relinquishes the title of President. This follows Mr. Blizard's resignation from the Board of Directors.
🚩 Red Flags
- Leadership transition/restructuring can sometimes indicate internal friction, though the filing explicitly states Blizard's resignation was not due to any disagreement with company operations or policies.
📋 Key Facts
- Jeffrey Blizard appointed as President, effective June 2, 2025.
- Antony Koblish to remain CEO but will no longer hold the title of President.
- Jeffrey Blizard resigned from the Board and Nominating and Corporate Governance Committee, effective June 2, 2025.
- Blizard's compensation includes a $475,000 base salary, 50% target annual bonus, and a $150,000 sign-on bonus.
- Equity awards granted to Blizard: 154,100 stock options (vesting over 3 years) and 104,800 RSUs (vesting over 4 years).
- Blizard brings significant medical device experience from Abiomed (J&J), Medtronic, Intuitive Surgical, and Boston Scientific.
TELA Bio, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 28, 2025. Key outcomes included the election of three Class III directors and stockholder approval for several amendments to the company's equity incentive plan and certificate of incorporation.
🚩 Red Flags
- The elimination of the 'evergreen' provision in the equity plan suggests a move toward more controlled, non-automatic share issuance, which is generally positive for existing shareholders but indicates a change in compensation structure.
📋 Key Facts
- Annual Meeting held virtually on May 28, 2025.
- Stockholders approved an amendment to increase authorized shares under the A&R 2019 Equity Incentive Plan by 3,500,000 shares and eliminate the 'evergreen' provision.
- Jeffrey Blizard, Vince Burgess, and Federica O’Brien were elected to the Board as Class III directors.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved a non-binding advisory vote for annual executive compensation votes (1-year frequency).
- An amendment to limit the liability of certain officers under Delaware law was approved.
TELA Bio, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025 and provided an updated corporate presentation.
📋 Key Facts
- Company released Q1 2025 financial results on May 8, 2025.
- The company furnished a press release (Exhibit 99.1) regarding its operations and financial condition.
- The company updated its corporate slide deck (Exhibit 99.2) for investor meetings.
TELA Bio, Inc. announced the U.S. commercial launch of expanded sizing options for its OviTex PRS Reinforced Tissue Matrix product line.
📋 Key Facts
- Date of event: March 31, 2025
- Product announcement: Commercial launch of larger sizes of OviTex PRS Reinforced Tissue Matrix in the U.S.
- The filing serves to incorporate a press release (Exhibit 99.1) regarding this product expansion.
TELA Bio, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2024. The company also provided an updated corporate presentation via Regulation FD disclosure.
📋 Key Facts
- Reported financial results for Q4 2024 and full fiscal year 2024 on March 20, 2025.
- Issued a corporate slide deck (Exhibit 99.2) to be used in investor meetings.
- The filing includes the earnings press release as Exhibit 99.1.
TELA Bio, Inc. filed an 8-K to announce its third quarter 2024 financial results and provide an updated corporate presentation for investor meetings.
📋 Key Facts
- Announced Q3 2024 financial results (ended September 30, 2024) via press release.
- Updated the company's corporate slide deck used for investor relations.
- Filed under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
TELA Bio, Inc. entered into an underwriting agreement on October 23, 2024, to conduct a public offering of common stock and pre-funded warrants. The offering aims to raise approximately $37.3 million in net proceeds to fund various corporate activities including R&D and working capital.
🚩 Red Flags
- Significant dilution: The issuance of 12 million shares plus up to 5.8 million warrants represents a substantial increase in the total share count, which will dilute existing shareholders.
- Pre-funded warrants: These are often used when investors want to avoid triggering certain ownership thresholds (9.99% limit mentioned) but still gain exposure, effectively acting as equity without immediate voting rights/share counts.
📋 Key Facts
- Offering includes 12,000,000 firm shares at $2.25 per share.
- Offering includes up to 5,800,000 pre-funded warrants at $2.2499 per warrant.
- Underwriters have a 30-day option to purchase an additional 2,670,000 shares.
- Expected net proceeds are approximately $37.3 million after fees and expenses.
- Pre-funded warrants are immediately exercisable at a price of $0.0001 per share.
- The offering is being conducted via an S-3 shelf registration statement.
TELA Bio, Inc. disclosed preliminary unaudited results for Q3 2024, showing year-over-year revenue growth and a slight compression in gross margins. The company also announced cost-cutting measures expected to reduce annualized operating expenses by $5M–$10M for FY2025.
🚩 Red Flags
- Significant cash burn: Cash reserves dropped from $46.7M (end of 2023) to $17.3M in nine months.
- Gross margin compression: Slight decrease from 69% to 68%.
📋 Key Facts
- Estimated Q3 2024 Revenue: $19.0 million (vs. $15.1 million in Q3 2023).
- Estimated Q3 2024 Gross Margin: ~68% (vs. 69% in Q3 2023).
- Cash and cash equivalents as of Sept 30, 2024: $17.3 million.
- Cash position decreased from $46.7 million on Dec 31, 2023, to $17.3 million in Q3 2024.
- Implemented cost-cutting measures expected to reduce annualized operating expenses by $5.0M to $10.0M for FY2025.
TELA Bio, Inc. filed an 8-K to announce its second quarter 2024 financial results and provide an updated corporate presentation for investor meetings.
📋 Key Facts
- Company reported Q2 2024 financial results on August 12, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the quarterly performance.
- An updated corporate slide deck was released for investor relations purposes (Exhibit 99.2).
- The company is classified as an 'emerging growth company'.
TELA Bio, Inc. announced the appointment of Jeffrey Blizard to its Board of Directors and provided results from its 2024 Annual Meeting of Stockholders. The meeting included the election of two Class II directors and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Jeffrey Blizard appointed to the Board of Directors on June 4, 2024, increasing the Board size to seven members.
- Mr. Blizard will serve as a Class III director with a term expiring at the 2025 Annual Meeting.
- Initial equity award for Mr. Blizard includes options for 9,300 shares and RSUs for 6,375 shares.
- Annual base retainer for Mr. Blizard is set at $45,000 plus $5,000 for service on the Nominating Committee.
- Kurt Azarbarzin and Antony Koblish were elected to serve as Class II directors until 2027.
- KPMG LLP was ratified as the independent registered public accounting firm for the 2024 fiscal year.
TELA Bio, Inc. announced a leadership transition in its commercial division, involving the termination of Chief Commercial Officer Peter Murphy and the appointment of Greg Firestone to the same role.
🚩 Red Flags
- Sudden departure of a C-suite officer (CCO) can sometimes signal internal friction, though 'without cause' is a neutral term often used for restructuring or mutual separation.
📋 Key Facts
- Peter Murphy was terminated without Cause as Chief Commercial Officer, effective May 19, 2024.
- Greg Firestone appointed as Chief Commercial Officer, effective May 20, 2024.
- Mr. Firestone previously served as the Company's Chief Business Officer since October 2017.
- The termination of Mr. Murphy includes a severance package per his employment agreement.
TELA Bio, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024 and provided an updated corporate slide deck for investor relations.
📋 Key Facts
- Company released Q1 2024 financial results on May 9, 2024.
- Updated a corporate slide deck (Exhibit 99.2) for use in upcoming investor meetings.
- The filing is an announcement of earnings and regulatory disclosure under Regulation FD.
TELA Bio, Inc. announced the U.S. commercial launch of its OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix on April 15, 2024.
📋 Key Facts
- Product Launch: OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix.
- Market Focus: U.S. commercial launch.
- Filing Date: April 15, 2024.
TELA Bio, Inc. issued an 8-K to announce its Q4 and full-year 2023 financial results, provide an updated corporate presentation, and announce the U.S. commercial launch of two new hernia mesh fixation devices.
📋 Key Facts
- Announced financial results for the fourth quarter and fiscal year ended December 31, 2023 (Item 2.02).
- Updated corporate slide deck provided to investors (Item 7.01).
- Announced U.S. commercial launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices (Item 8.01).
TELA Bio, Inc. has completed the sale of its distribution rights for its NIVIS® Fibrillar Collagen Pack to MiMedx Group, Inc. The transaction includes an immediate cash payment and potential milestone payments based on future sales.
🚩 Red Flags
- Divestiture of distribution rights may indicate a strategic shift or a need for immediate liquidity, though common in micro-cap biotech/medtech companies seeking to focus on core R&D.
📋 Key Facts
- Completed sale of NIVIS® Fibrillar Collagen Pack distribution rights to MiMedx Group, Inc. on March 15, 2024.
- Initial upfront payment of $5.0 million received.
- Contingent consideration (earn-out) ranging from a minimum of $3.0 million to a maximum of $7.0 million based on net sales over the next two years.